Calliditas Therapeutics AB (NAS:CALT)
$ 22 -0.19 (-0.86%) Market Cap: 590.48 Mil Enterprise Value: 589.81 Mil PE Ratio: 0 PB Ratio: 18.64 GF Score: 49/100

Q2 2021 Calliditas Therapeutics AB Earnings Call Transcript

Aug 19, 2021 / 12:30PM GMT
Release Date Price: $21.91 (-0.45%)
Operator

Ladies and gentlemen, welcome to the Calliditas Therapeutics Q2 2021 Report. Today, I am pleased to present the CEO, Renee Lucander; the CFO, Fredrik Johansson; and the President of North America, Andrew Udell.

(Operator Instructions)

Speakers, please begin.

Fredrik Johansson;publ;CFO
Calliditas Therapeutics AB

()-

Thank you. We start at Page 2 at the forward-looking statement. This presentation contains forward-looking statements. Any forward-looking statements in this presentation are based on management's current expectations and beliefs, and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any certain statements contained in this presentation.

And we would, thus, caution you not to place undue reliance on any forward-looking statements, which speaks only as of today, they are made. Calliditas Therapeutics disclaims any obligation to publicly update or revise any such statements,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot